Welcome to the International Journal of Biological Markers, a distinguished publication under SAGE Publications Ltd that has been a vital resource in the fields of Cancer Research, Clinical Biochemistry, Oncology, and Pathology and Forensic Medicine since its inception in 1986. With a commitment to disseminating high-quality research, the journal enjoys a robust impact highlighted by its Q2 and Q3 rankings across multiple categories in 2023, as evidenced by its Scopus rankings placing it in respectable percentiles. Based in Italy, this journal serves a global audience of researchers, clinicians, and students eager to keep abreast of the latest discoveries involving biological markers and their applications in medicine. Emphasizing rigorous peer review and scholarly integrity, the International Journal of Biological Markers plays a crucial role in advancing knowledge that can significantly impact clinical practices and enhance patient care.

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

BMC Cardiovascular Disorders is a premier open access journal dedicated to the field of cardiology and cardiovascular medicine, published by BMC, a leading publisher in the scientific community. Since its inception in 2001, this journal has provided a platform for high-quality research, showcasing innovative studies and critical reviews that contribute to the understanding and management of cardiovascular diseases. With an impressive impact factor and a rank in the Q2 category for 2023 within its field, BMC Cardiovascular Disorders stands at the forefront of cardiovascular research, enabling accessibility to a wealth of information that fosters collaboration and advancements in patient care. The journal's commitment to open access ensures that research is widely disseminated and easily accessible to researchers, practitioners, and students globally, enhancing the dialogue around cardiovascular health and disease prevention. Located in the United Kingdom, BMC Cardiovascular Disorders consistently aims to promote excellence in the study and treatment of cardiovascular conditions, encouraging the exchange of knowledge that ultimately benefits public health.

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

EBioMedicine is an esteemed open-access journal published by ELSEVIER, dedicated to advancing the fields of biochemistry, genetics, and molecular biology, as well as medicine. Since its inception in 2014, EBioMedicine has established itself as a prominent platform for disseminating high-quality research, evidenced by its impressive rankings in Scopus, where it holds a Q1 category in both Biochemistry, Genetics and Molecular Biology and Medicine for 2023. With an exceptional impact factor that places it in the top percentiles (97th in Medicine and 93rd in Biochemistry), the journal is recognized for its rigorous peer-review process and its commitment to fostering scientific collaboration. Open access since its launch, EBioMedicine ensures that groundbreaking research is readily available to researchers, professionals, and students worldwide, enhancing knowledge dissemination and driving innovation in these crucial fields. For those seeking to stay at the forefront of biomedical research, EBioMedicine is an invaluable resource.

Proteomics Clinical Applications, published by Wiley-VCH Verlag GmbH, is a pivotal journal in the realm of Clinical Biochemistry, with an impressive track record since its inception in 2007, continuing its impactful contributions to 2024. With an ISSN of 1862-8346 and an E-ISSN of 1862-8354, this prestigious journal currently holds a commendable Q2 ranking in Clinical Biochemistry, situated at the 54th percentile among its peers within Scopus rankings. Dedicated to the advancement of proteomics and its applications in clinical settings, Proteomics Clinical Applications serves as a bastion for innovative research, fostering knowledge exchange among scientists, healthcare professionals, and students alike. Through its focus on novel methodologies and translational research, the journal aims to bridge the gap between laboratory findings and clinical practice, significantly impacting patient care and outcomes. Although not open access, its content is accessible through various academic databases, ensuring that vital research reaches its intended audience.

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.